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Abstract
Background: Neutrophil gelatinase associated lipocalin (NGAL) is a biomarker of kidney injury. We examined
plasma levels of NGAL in a cohort of 57 kidney allograft recipients (Tx group, 39 ± 13 years), a uraemic group of
40 patients remaining on the waiting list (47 ± 11 years) and a control group of 14 healthy subjects matched for
age, sex and body mass index (BMI). The kidney graft recipients were studied at baseline before transplantation
and 3 and 12 months after transplantation and the uraemic group at baseline and after 12 months.
Methods: NGAL was measured using a validated in-house Time-Resolved Immuno-flourometric assay (TRIFMA).
Repeated measurements differed by < 10% and mean values were used for statistical analyses. Spearman rank
order correlation analysis and the Kruskal-Wallis non-parametric test were used to evaluate the association of NGAL
concentrations with clinical parameters.
Results: Plasma NGAL levels before transplantation in the Tx and uraemic groups were significantly higher than in
the healthy controls (1,251 μg/L, 1,478 μg/L vs. 163 μg/L, p < 0.0001). In the Tx group NGAL concentrations were
associated with serum creatinine (R = 0.51, p < 0.0001), duration of end-stage renal failure (R = 0.41, p = 0.002) and
leukocyte count (R = 0.29, p < 0.026). At 3 and 12 months plasma NGAL concentrations declined to 223 μg/L and
243 μg/L, respectively and were associated with homocysteine (R = 0.39, p = 0.0051 and R = 0.47, p = 0.0007).
Conclusions: Plasma NGAL is a novel marker of kidney function, which correlates to duration of end-stage renal
failure (ESRD) and serum creatinine in uraemic patients awaiting kidney transplantation. Plasma NGAL is associated
with homocysteine in transplanted patients. The prognostic value of these findings requires further studies.
Background
Neutrophil gelatinase associated lipocalin (NGAL) also
known as Lipocalin 2 or Lcn2 is a 25 kDa protein identi-
fied originally as a protein associated with matrix metal-
loproteinase 9 (MMP-9) of human neutrophils [1].
Lipocalins are extracellular proteins which share a com-
mon tertiary structure that forms a barrel-like hydropho-
bic ligand binding site [2]. When bound to MMP-9,
NGAL protects it from proteolytic degradation sustaining
the proteolytic activity of MMP-9. No specific receptor
for NGAL has yet been identified. However, the endocy-
tosis low density lipoprotein receptor Megalin has been
shown to bind NGAL with high affinity suggesting that
NGAL is taken up by host cells [3]. NGAL has been sug-
gested as a bacteriostatic agent indicating involvement of
NGAL in the innate immune response [4-7]. Moreover,
serum levels of NGAL have been reported to be useful in
discriminating between acute bacterial and viral infec-
tions [8]. Expression of NGAL is prominent in secondary
granules of human neutrophils [9,10]. NGAL is induced
by bacterial lipopolysaccharides [11], dexamethasone
[12,13], growth factors and cytokines such as insulin-like
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growth factor I (IGF-I) [12,14] and interleukin 1 (IL-1)
[15-18]. Upon nephrotoxic and/or ischemic injury NGAL
levels are highly increased in kidney cortical tubules,
blood and urine [18]. In vascular smooth muscle cells
NGAL expression is induced in response to vascular
injury and depends on nuclear factor kappa B (NF-kB)
expression [19]. Interestingly, the interaction of NGAL
with MMP-9 may be a mechanism by which the proteo-
lytic activity of MMP-9 is modulated in the vascular
repair process indicating a role for NGAL in cardiovascu-
lar disease (CVD). Expression of NGAL is induced upon
activation of Toll-like receptors (TLRs) on immune cells
constituting an acute phase response to infection [20].
NGAL has received considerable attention due to its role
as an early biomarker in kidney disease [21-23]. In a
cross-sectional study of 100 kidney allograft recipients
serum NGAL was shown to correlate with kidney func-
tion [24] and it has been studied in several clinical set-
tings of acute kidney injury (AKI) [25-30]. Haase et al.
[26] confirmed the predictive and prognostic value of
NGAL as an early biomarker for AKI in a meta-analysis
involving 19 studies ( > 2,500 patients). Induction
of NGAL after kidney injury precedes the elevation of
classical markers for kidney damage [27,28], e.g. serum
creatinine, urinary N-acetyl glucosamidase and b2-micro-
globulin levels. In studies of renal failure in mice the
functional significance of up-regulation of NGAL has
been suggested to be renal protective [18,31]. The pre-
sent study aimed to investigate the possible relationship
between plasma NGAL levels and clinical parameters in
a prospective study of non-diabetic uraemic patients.
Methods
Study procedure
The study population consisted of 97 non-diabetic urae-
mic patients and was based on a prospective, observa-
tional, national multicenter study. Data on the study
population has been published previously [32]. In brief, 57
of the patients were scheduled for living donor kidney
transplantation in the period between January 2006 and
March 2008 at the four Danish transplantation centres:
Rigshospitalet, Skejby, Odense, and Herlev University Hos-
pitals (Tx group, age 39 ± 13 years). A control group of 40
patients from the transplantation waiting list at Rigshospi-
talet and Herlev University Hospitals (uraemic group, age
47 ± 11) was included. The study also included a group of
healthy controls (n = 14). The healthy controls were BMI
and sex matched and was recruited from public announ-
cing. The regional ethical committee (# KF 01279825) and
The Data Protection Agency (#2006-41-5640) approved
the study. Participants gave their informed written con-
sent. Transplanted participants were examined before
transplantation and 3 and 12 months after transplantation.
The uraemic controls were examined at baseline and 12
months later. The examinations were done after an over-
night fast including coffee, tobacco, and exercise absence
for 10 hours. Anti-hypertensive medication was allowed in
the morning. A 75-gram oral glucose tolerance test
(OGTT) was performed on all patients according to the
WHO/ADA 2007 criteria [33]. An insulin sensitivity index
was calculated according to Matsuda et al. [34]. Immuno-
suppression varied to some extent between the centers.
Induction therapy included basiliximab (Simulect; Novar-
tis), daclizumab (Zenapax; Roche), or antithymocyte
globulin (Thymoglobulin; Genzyme B.V.). The majority of
patients received 100-500 mg of intravenous methylpred-
nisolone preoperatively, and treatment with oral predniso-
lone was started by 20-100 mg/d and was tapered to a
dose of 7.5-10 mg at 3 months and to 5-7.5 mg at 9-12
months. Rejection episodes, indicated by increased plasma
creatinine of 20% or greater for 2 days, or biopsy proven,
were treated with intravenous methylprednisolone, 500
mg, for 3-5 days. For each patient the accumulated corti-
costeroid dose within the first 90 days was calculated and
given in equivalents of prednisolone dose in grams. Forty-
three patients started on cyclosporine (Sandimune Neoral;
Novartis) at a dose of 2.5-6 mg/kg twice daily tapered to a
trough level of whole-blood concentration of 150-300 μg/
L for the first 3 months and 100-150 μg/L thereafter. The
remaining 14 patients started on tacrolimus (Prograf;
Astellas) at a dose of 0.075-0.15 mg/kg twice daily tapered
to a whole-blood concentration of 8-15 μg/L for the first 3
months and 5-10 μg/L thereafter. A few patients (n = 8)
changed from one treatment modality to another during
the course of the study, and two patients were changed to
rapamycin (Rapamune; Wyeth) treatment.
After 10 minutes of rest in the supine resting position
arterial blood pressure (BP) was measured in triplicate
from the arm opposite to a fistula or dialysis catheter.
Mean arterial BP (MAP) was calculated on the basis of
these three measurements. Renal function was estimated
by the Cockcroft-Gault formula (eGFR) [35]. Fasting
blood samples were drawn from an antecubital vein and
aliquots of EDTA-plasma were stored at -80°C. Examiners
were blinded with regards to the clinical and metabolic
status of patients and clinical information was analyzed
and described after completion of the data collection.
Anti-hypertensive treatment mainly included b-blockade,
calcium channel blockade, angiotensin-II-blockade and
diuretics. Anti-hypertensive medication was stopped at the
time of transplantation and thereafter titrated aiming a BP
below 130/80 mmHg. Clinical characteristics of the study
group are shown in Table 1.
Statistical methods
Data analyses using clinical data were performed using
Statistical Analysis Software (SAS®) version 9.1. Unless
specified otherwise, continuous data is described as mean
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± SD for normal distributions, and median and range for
skewed distributions. Paired data within groups were
compared by t-tests for normally distributed data, and
group comparisons of continuous data were performed
using two-sample t-test for normally distributed data and
non-parametric Wilcoxon Rank Sum Test for not-normal
distributed data. Chi squared or Fisher’s exact tests were
used for group comparisons between categorical data.
Correlation analysis was done using Spearman Rank
Analysis. Scatter plot, regression analysis and difference
vs. average plots were performed using STATA version
11.1. P-values below 0.05 for parametric and non-para-
metric tests were considered significant.
NGAL assay procedure
Plasma NGAL levels were determined using stored EDTA-
plasma by an in-house time resolved immunofluorometric
(TRIFMA) sandwich-type assay based on anti-NGAL
antibodies and recombinant NGAL from R&D Systems
(Abingdon, UK). Microtitre plates (Nunc, Roskilde,
Denmark) were coated overnight at 4°C with monoclonal
capture NGAL antibody dissolved in phosphate buffered
saline (PBS). Plates were blocked for 2 hours at room tem-
perature with assay buffer (1% (w/v) BSA and 0.05% (v/v)
Tween 20 in PBS) and washed three times with 0.05% (v/v)
Tween 20 in PBS (PBST). Standards were prepared using
recombinant NGAL by serial dilutions of up to three dec-
ades. A pool of plasma from five healthy adult donors and
plasma pool spiked with recombinant NGAL were
included as internal controls. Between each step of the
assay the plates were washed three times with PBST. Sam-
ples and controls were diluted 1:200 in assay buffer and
incubated overnight at 4°C. Plates were then incubated
with biotinylated monoclonal NGAL antibody in assay buf-
fer and then incubated with streptavidin-europium (Perkin
Elmer Life Sciences, Finland). Enhancement solution
Table 1 Demographic and clinical data, from 57 kidney allograft recipients (Tx group), 40 uraemic patients (uraemic
controls) and 14 healthy controls, at baseline before transplantation.
Tx-group Uraemic group Healthy controls
N = 57 N = 40 N = 14
Age (years, SD) 39 ± 13 47 ± 11 39 ± 11
Gender (male/female) 38/19 27/13 5-Sep
ESRD duration (months, range) 24 (0-134) 45 (1-168) -
BMI (kg/m2) 24 ± 4 24 ± 4 24 ± 3
Waist-hip ratio 0.92 ± 0.09 0.91 ± 0.08 0.81 ± 0.08***
Ever Smoking, n (%) 27 (47) 26 (65) 9 (64)
Diagnoses n (%)
Glomerulonefritis 28 (49) 13 (33) -
Hypertensive 5 (9) 11 (28) -
Kidney disease
Vasculitis 1 (2) 1 (3) -
PKD 3 (5) 7 (18) -
Other/unknown 20 (35) 8 (20) -
Apoplexi 3 (5) 3 (8) -
Former transplanted 11 (19) 10 (25) -
Dialysis-status
HD 28 (49) 28 (70) -
CAPD 19 (33) 9 (27) -
Pre-dialysis 10 (18) 3 (8) -
First degree relatives with DM 2 (4) 4 (10) 2 (14)
Fasting p-glucose (mmol/L) 5.1 ± 0.5 5.1 ± 0.5 5.0 ± 0.3
P-glucose at 2-hours (mmol/L) 7.4 ± 1 7.5 ± 2 5.4 ± 1***
HbA1c (%) 5.2 ± 0.4 5.2 ± 0.4 5.2 ± 0.2
Insulin sensitivity index 6.8 ± 4.0 7.9 ± 5.1 14.7 ± 7.0***
Insulin secretion index 36.9 ± 18.5 31.4 ± 17.3 27 ± 14
Systolic BP (mmHg) 142 ± 21 141 ± 24 118 ± 10***
Diastolic BP (mmHg) 85 ± 13 83 ± 14 73 ± 8***
Pulse 69 ± 11 72 ± 11 61 ± 10***
Data are presented as mean ± SD or median and range, numbers (n) and percent (%). HD: hemodialysis, CAPD: continuous ambulatory peritoneal dialysis, ESRD:
end stage renal disease, Tx: transplantation, PKD: polycystic kidney disease, DM: diabetes mellitus, BP: blood pressure. Wilcoxon Rank Sum Test or two sample t-
test used where appropriate to test: uraemic patients vs. Healthy controls; *p < 0.05, **p < 0.005, ***p < 0.0005.
Magnusson et al. BMC Nephrology 2012, 13:8
http://www.biomedcentral.com/1471-2369/13/8
Page 3 of 8
(Perkin Elmer Life Sciences) was added and plates were
measured in a time-resolved fluorometer. Standards, sam-
ples and non-specific binding were analysed in duplicate.
Non-specific background (NSB) averaged 5000 counts per
second (cps), the lowest standard 8000 cps and the highest
standard 1.4 × 10E06 cps. The detection limit was esti-
mated at < 0.1 μg/L based on NSB + 3 SD. The coefficient
of variation (CV) within assays of standards controls and
unknown samples averaged less than 7% based on repeti-
tive runs of identical plasma samples. The CV between
assays was determined by repetitive analysis of standards
and control samples. After 15 different runs the between
assay CVs averaged < 12%. Repetitive freezing and thawing
of plasma from the healthy donors was tested every other
cycle up to eleven cycles and did not alter the levels of
NGAL significantly (data not shown) in line with pre-
viously published data [36]. The linearity of the assay, esti-
mated with plasma samples using serial dilutions up to
1:800 indicated a high precision over a wide range of con-
centrations (mean CV = 4.4%, range; 0.5-9%). Minor
increases of NGAL levels was found with increasing dilu-
tions in samples with high levels of NGAL ( > 1400 μg/L,
CV = 8%).
Recovery of recombinant NGAL
Recovery was based on plasma samples containing high,
medium or low levels of NGAL. These samples were
spiked with different amounts of exogenously added
recombinant NGAL and diluted 1:200 to a final concen-
tration of 3, 9 or 30 μg/L of recombinant NGAL. Samples
without added NGAL were used as controls. The assay
was analyzed with six replicates and repeated twice. For
each sample the recovery was estimated as the mean per-
centage of the measured concentrations compared to the
expected concentrations.
Comparison between platforms
The in-house NGAL assay was compared back to back
with a commercially available ELISA kit (036, Bioporto
Diagnostics, Gentofte, Denmark) with samples of plasma
and serum; 34 uraemic plasma samples and a collection
of 33 serum samples were run on both platforms. The
ELISA assay was recently validated [36]. The ELISA kit
analysis was carried out as suggested by the manufac-
turer. Samples used for the in-house NGAL assay were
prepared and diluted 1:200 as described above. The
assays were performed on the same day to minimize day
to day variation.
Results
The relationship between plasma NGAL and clinical
characteristics
NGAL data were not normally distributed and Spear-
man rank order correlation analysis and the Kruskal-
Wallis non-parametric test were used to evaluate the asso-
ciation of NGAL concentrations with clinical parameters.
In the Tx group mean NGAL levels were 1,251 ± 438 μg/
L prior to Tx (time = 0) vs. 223 ± 110 μg/L (p < 0.001)
and 243 ± 86 μg/L (p < 0.001) at 3 and 12 months post
Tx, respectively, compared to 163 ± 29 μg/L in the healthy
controls (Tx-group at time = 0 vs. healthy, p < 0.0005).
Mean NGAL levels are shown in Table 2. Following trans-
plantation the NGAL levels were significantly reduced, but
remained above the levels found in the healthy controls
(243 ± 86 μg/L vs. 163 ± 29 μg/L, p < 0.0001). NGAL
levels in the uraemic group remaining on the waiting list
were significantly higher than in the Tx group at baseline
before transplantation (1,478 ± 403 μg/L vs. 1,251 ± 438
μ/L, p < 0.05) and may probably be explained by a signifi-
cant higher mean age and duration of ESRD in the urae-
mic group (47 vs. 39 years, and 45 vs. 24 months) and
hence differences in serum creatinine. There was no sig-
nificant difference in NGAL levels between the groups
when stratifying for OGTT status, immunosuppression
treatment or age in the Tx group (data not shown).
Relationship between NGAL and kidney function
Before Tx plasma NGAL concentrations were highly asso-
ciated with serum creatinine (R = 0.51, p < 0.0001) and
leukocyte count (R = 0.29, p < 0.026) in concordance with
previously published data [21,26,37]. At three and 12
months post Tx NGAL levels were associated with homo-
cysteine (R = 0.39, p = 0.005 and R = 0.47, p = 0.0007) and
at 12 months the association with leukocyte count was
mitigated reflecting the partially restored kidney function.
The relationship between NGAL levels and serum creati-
nine is shown in Figure 1.
We found no relationship between NGAL levels and
increased blood pressure defined as systolic BP > 130
mmHg and/or diastolic BP ≥ 90 mmHg in either groups
both before and after transplantation. However, eGFR was
significantly lower in the hypertension group after 12
months (eGFR = 71 ± 26 versus eGFR = 84 ± 18, p < 0.05).
Recovery of recombinant NGAL
The median recovery of exogenously added recombinant
NGAL in plasma was 90% for samples spiked to 3 μg/L,
Table 2 Kidney allograft recipient patients vs. waiting list
patients and within groups *p < 0.05, ***p < 0.0005, all
patients vs. healthy controls §§§p < 0.0005 (students
paired t-test).
Tx group Waiting list Healthy
NGAL μg/L
Time = 0
1,251 ± 438 1,478 ± 403* 163 ± 29§§§
NGAL μg/L
Time = 12 months
243 ± 86*** 1,668 ± 496 -
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97% for samples with 9 μg/L and 89% for samples with
30 μg/L. The overall median recovery was 91%. The
results are shown in Table 3.
Comparison between platforms
Two samples were omitted from the analysis due to
high standard deviations ( > 15%) in the in-house assay
and 16 samples were out of range ( > 900 μg/L) in the
ELISA assay and were omitted. These samples were re-
measured, and confirmed (average CV 6%, range; 4-7%),
with the in-house assay in four serial dilutions (up to
1:800) (data not shown). For the in-house assay the con-
centrations of NGAL ranged between 83 μg/L and 563
μg/L with mean 215 μg/L. For the ELISA, concentra-
tions ranged between 57 μg/L and 496 μg/L with mean
186 μg/L. The two methods were compared using scat-
ter plot, regression analysis and a Bland-Altman plot
[38], Figure 2. The Bland-Altman plot shows a random
Figure 1 Relationship between serum creatinine and plasma NGAL levels in the kidney allograft recipients . Squares: before
transplantation, circles: three months after transplantation, triangles: 12 months after transplantation. Insert: Three and 12 months after
transplantation with expanded resolution.
Table 3 Recovery of NGAL, internal replicates (n = 6), external replicates (n = 2)
NGAL level in sample Spike μg/L Expected μg/L Measured μg/L Recovery (%)
Low 3 3.8 3.8 99.9
9 9.8 9.9 100.8
30 30.8 27.4 89.1
Medium 3 9.8 8.1 82.9
9 15.8 15.0 94.6
30 36.8 31.9 86.6
High 3 11.5 9.9 86.2
9 17.5 16.4 94.1
30 38.5 34.8 90.6
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distribution around the mean with a proportional differ-
ence of approximately 14% on average with higher levels
reported by the TRIFMA assay. The result of a Pitman’s
test showed that there was no significant difference (p =
0.55) between the measuring errors of the two methods.
Regression analysis, shown in Figure 3, yielded an R
value of 0.96. Taken together these data indicate a high
concordance between the assays.
Discussion
This prospective study investigated the level of plasma
NGAL in a cohort of kidney allograft recipients and
included a uraemic control group and a group of
healthy controls. The main findings of this study were
that plasma NGAL levels were markedly higher in
patients prior to transplantation compared to the levels
measured at three and twelve months after transplanta-
tion. Plasma NGAL levels remained constant between
three and twelve months but was still significantly
higher than the level in the healthy control group
reflecting that the kidney function is not fully restored
as seen by lowered eGFR. In the Tx-group before trans-
plantation we found that NGAL paralleled measures of
kidney function and correlated to serum creatinine and
leukocyte count confirming previous reports showing
that elevated levels of NGAL reflect dysfunction of the
kidney [21,26,37,39]. At three and twelve months after
transplantation we found that high plasma NGAL levels
were associated with elevated plasma homocysteine
which may illustrate the atherosclerotic component of
kidney disease. Patients with chronic kidney disease
(CKD) (within stage 3 CKD category) have an increased
risk above 20% by the Framingham risk score for devel-
oping cardiovascular disease (CVD) [40,41]. A recent
study reported significant associations between plasma
NGAL, plasma homocysteine, eGFR and serum creati-
nine in patients with advanced carotid atherosclerosis
[42] highlighting the hypothesis of NGAL as a mediator
of vascular remodeling and potential role in CVD
[43,44]. The relevance of this association for the present
study is unresolved, but raises the question of a possible
relationship between homocysteine and NGAL since
homocysteine is a known risk factor of CVD [45]. There
was no clear relationship between NGAL and BP in the
Tx- group prior to transplantation or in the uraemic
group (remaining on the waiting list for one year). Sev-
eral studies have reported an association between NGAL
and BP. First, Eleneihoum et al. reported an association
between NGAL and diastolic blood pressure in middle
aged patients with early asymptomatic atherosclerosis
[43]. Secondly, Bolignano et al. found association
between NGAL and systolic BP in patients with conges-
tive heart failure [43]. Thirdly, Malyszko et al. showed
association of NGAL to hypertension in patients with
stable coronary artery disease and normal kidney func-
tion [46] and found an association in renal allograft reci-
pients in a cross-sectional study [24]. Finally, Giaginis et
al. reported association between NGAL and hyperten-
sion in a patient group with carotid atherosclerosis [42].
In most of these studies BP was also associated to
eGFR, serum creatinine or both. In the study of Giaginis
et al., hypertensive patients presented with increased
serum creatinine levels and reduced eGFR indicating
that the association between NGAL and hypertension
may be secondary to the effect of renal impairment. The
reason why we did not find any association between BP,
NGAL and serum creatinine, both before and three and
12 months post-Tx may be due to the limited size of
our cohort. However, high BP was associated with
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reduced eGFR at twelve months, supporting the idea
that NGAL is secondary to eGFR in terms of BP.
A limitation of our study is that we included a rather
small group of patients in CKD stage 5 (eGFR < 15 ml/
min), but paired longitudinal data were available to com-
pensate for this. Also, the uraemic control group consists
of older patients and with longer duration of uraemia. The
use of serum creatinine and eGFR values in uraemic
patients is biased and influenced by dialysis, weight and
muscles of the patient and should be interpreted with
caution.
Conclusions
Plasma NGAL correlated to serum creatinine, eGFR and
duration of ESRD and to serum creatinine and eGFR
after transplantation. Moreover, plasma NGAL was asso-
ciated with homocysteine after transplantation. It
remains to be clarified whether the association between
NGAL and homocysteine is caused by presently
unknown factors or may be due to a further extension
of the atherosclerotic component of kidney disease.
Acknowledgements
We gratefully acknowledge Joan Hansen, The Medical Research Laboratories,
Institute of Clinical Medicine, Faculty of Health Sciences, Aarhus University
Hospital, for technical assistance.
Author details
1The Medical Research Laboratories, Faculty of Health Sciences, Aarhus
University, Aarhus, Denmark. 2Department of Endocrinology and Internal
Medicine, Aarhus University Hospital, Aarhus, Denmark. 3Department of
Nephrology, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
Denmark. 4Department of Renal Medicine C, Aarhus University Hospital,
Skejby, Denmark. 5Department of Nephrology, Copenhagen University
Hospital,Herlev Hospital, Copenhagen, Denmark. 6Department of
Nephrology, Odense University Hospital, Odense, Denmark.
Authors’ contributions
NEM and AF conceived the study. NEM was responsible for the assay
design, measurements of NGAL, statistical analyses and for writing the paper.
MH was responsible for the statistical analyses involving clinical data. MH,
KAJ, JMH, CB and BFR were responsible for the prospective study used for
these analyses. All authors’ contributed to the manuscript. All authors have
read and approved the final manuscript.
The results presented in this paper have not been published previously in
whole or part, except in abstract form.
Competing interests
The authors declare that they have no competing interests.
Received: 8 July 2011 Accepted: 10 February 2012
Published: 10 February 2012
References
1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N: Isolation and primary
structure of NGAL, a novel protein associated with human neutrophil
gelatinase. J Biol Chem 1993, 268(14):10425-10432.
2. Patel RC, Lange D, McConathy WJ, Patel YC, Patel SC: Probing the
structure of the ligand binding cavity of lipocalins by fluorescence
spectroscopy. Protein Eng 1997, 10(6):621-625.
3. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N:
The endocytic receptor megalin binds the iron transporting neutrophil-
gelatinase-associated lipocalin with high affinity and mediates its
cellular uptake. FEBS Lett 2005, 579(3):773-777.
4. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK:
The Neutrophil Lipocalin NGAL Is a Bacteriostatic Agent that Interferes
with Siderophore-Mediated Iron Acquisition. Mol Cell 2002, 10(5):1033,
1043..
5. Yang J, Mori K, Li JY, Barasch J: Iron, lipocalin, and kidney epithelia. Am J
Physiol Renal Physiol 2003, 285(1):F9-18.
6. Berger T, Togawa A, Duncan GS, Elia AJ, You-Ten A, Wakeham A, Fong HE,
Cheung CC, Mak TW: Lipocalin 2-deficient mice exhibit increased
sensitivity to Escherichia coli infection but not to ischemia-reperfusion
injury. Proc Natl Acad Sci USA 2006, 103(6):1834-1839.
7. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, Akira S,
Aderem A: Lipocalin 2 mediates an innate immune response to bacterial
infection by sequestrating iron. Nature 2004, 432(7019):917-921.
8. Xu SY, Pauksen K, Venge P: Serum measurements of human neutrophil
lipocalin (HNL) discriminate between acute bacterial and viral infections.
Scand J Clin Lab Invest 1995, 55(2):125-131.
9. Axelsson L, Bergenfeldt M, Ohlsson K: Studies of the release and turnover
of a human neutrophil lipocalin. Scand J Clin Lab Invest 1995,
55(7):577-588.
10. Seveus L, Amin K, Peterson CG, Roomans GM, Venge P: Human neutrophil
lipocalin (HNL) is a specific granule constituent of the neutrophil
granulocyte. Studies in bronchial and lung parenchymal tissue and
peripheral blood cells. Histochem Cell Biol 1997, 107(5):423-432.
11. Sunil VR, Patel KJ, Nilsen-Hamilton M, Heck DE, Laskin JD, Laskin DL: Acute
endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in
lung and liver. Exp Mol Pathol 2007, 83(2):177-187.
12. Liu M, Prisco M, Drakas R, Searles D, Baserga R: 24p3 in Differentiation of
Myeloid Cells. J Cell Physiol 2005, 205(2):302-309.
13. Garay-Rojas E, Harper M, Hraba-Renevey S, Kress M: An apparent autocrine
mechanism amplifies the dexamethasone- and retinoic acid-induced
expression of mouse lipocalin-encoding gene 24p3. Gene 1996,
170(2):173-180.
14. Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N:
Wound healing and expression of antimicrobial peptides/polypeptides
in human keratinocytes, a consequence of common growth factors.
J Immunol 2003, 170(11):5583-5589.
15. Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, Yarmush ML:
Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a
discriminatory marker of the hepatocyte-secreted protein response to
IL-1beta: a proteomic analysis. Biotechnol Bioeng 2005, 91(4):502-515.
16. Cowland JB, Sorensen OE, Sehested M, Borregaard N: Neutrophil
gelatinase-associated lipocalin is up-regulated in human epithelial cells
by IL-1 beta, but not by TNF-alpha. J Immunol 2003, 171(12):6630-6639.
17. Pawluczyk IZ, Furness PN, Harris KP: Macrophage-induced rat mesangial
cell expression of the 24p3-like protein alpha-2-microglobulin-related
protein. Biochim Biophys Acta 2003, 1645(2):218-227.
18. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, Schmidt-Ott KM,
Chen X, Li JY, Weiss S, Mishra J, Cheema FH, Markowitz G, Suganami T,
Sawai K, Mukoyama M, Kunis C, D’Agati V, Devarajan P, Barasch J: Endocytic
delivery of lipocalin-siderophore-iron complex rescues the kidney from
ischemia-reperfusion injury. J Clin Invest 2005, 115(3):610-621.
19. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P, Yan ZQ:
Induction of neutrophil gelatinase-associated lipocalin in vascular injury
via activation of nuclear factor-kappaB. Am J Pathol 2006,
169(6):2245-2253.
20. Draper DW, Bethea HN, He YW: Toll-like receptor 2-dependent and
-independent activation of macrophages by group B streptococci.
Immunol Lett 2006, 102(2):202-214.
21. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J,
Devarajan P: Identification of neutrophil gelatinase-associated lipocalin as
a novel early urinary biomarker for ischemic renal injury. J Am Soc
Nephrol 2003, 14(10):2534-2543.
22. Supavekin S, Zhang W, Kucherlapati R, Kaskel FJ, Moore LC, Devarajan P:
Differential gene expression following early renal ischemia/reperfusion.
Kidney Int 2003, 63(5):1714-1724.
23. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV: Kidney injury
molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced
renal injury. Am J Physiol Renal Physiol 2004, 286(3):F552-63.
Magnusson et al. BMC Nephrology 2012, 13:8
http://www.biomedcentral.com/1471-2369/13/8
Page 7 of 8
24. Malyszko J, Malyszko JS, Mysliwiec M: Serum neutrophil gelatinase-
associated lipocalin correlates with kidney function in renal allograft
recipients. Clin Transplant 2009, 23(5):681-686.
25. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT:
Association between increases in urinary neutrophil gelatinase-
associated lipocalin and acute renal dysfunction after adult cardiac
surgery. Anesthesiology 2006, 105(3):485-491.
26. Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D,
Haase M: Novel and conventional serum biomarkers predicting acute
kidney injury in adult cardiac surgery–a prospective cohort study. Crit
Care Med 2009, 37(2):553-560.
27. Zappitelli M, Washburn KK, Arikan AA, Loftis L, Ma Q, Devarajan P, Parikh CR,
Goldstein SL: Urine neutrophil gelatinase-associated lipocalin is an early
marker of acute kidney injury in critically ill children: a prospective
cohort study. Crit Care 2007, 11(4):R84.
28. Wheeler DS, Devarajan P, Ma Q, Harmon K, Monaco M, Cvijanovich N,
Wong HR: Serum neutrophil gelatinase-associated lipocalin (NGAL) as a
marker of acute kidney injury in critically ill children with septic shock.
Crit Care Med 2008, 36(4):1297-1303.
29. Ling W, Zhaohui N, Ben H, Leyi G, Jianping L, Huili D, Jiaqi Q: Urinary IL-18
and NGAL as early predictive biomarkers in contrast-induced
nephropathy after coronary angiography. Nephron Clin Pract 2008, 108(3):
c176-81.
30. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS,
Dobrzycki S: Neutrophil-gelatinase-associated lipocalin and renal function
after percutaneous coronary interventions. Am J Nephrol 2006,
26(3):287-292.
31. Mishra J, Mori K, Ma Q, Kelly C, Yang J, Mitsnefes M, Barasch J, Devarajan P:
Amelioration of ischemic acute renal injury by neutrophil gelatinase-
associated lipocalin. J Am Soc Nephrol 2004, 15(12):3073-3082.
32. Hornum M, Jorgensen KA, Hansen JM, Nielsen FT, Christensen KB,
Mathiesen ER, Feldt-Rasmussen B: New-onset diabetes mellitus after
kidney transplantation in Denmark. Clin J Am Soc Nephrol 2010,
5(4):709-716.
33. American Diabetes Association: Diagnosis and classification of diabetes
mellitus. Diabetes Care 2011, 34(Suppl 1):S62-9.
34. Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral
glucose tolerance testing: comparison with the euglycemic insulin
clamp. Diabetes Care 1999, 22(9):1462, 1470.
35. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum
creatinine. Nephron 1976, 16(1):31-41.
36. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV: Neutrophil
gelatinase-associated lipocalin (NGAL): validation of commercially
available ELISA. Scand J Clin Lab Invest 2010, 70(5):374-382.
37. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B,
Dobrzycki S, Mysliwiec M: Neutrophil gelatinase-associated lipocalin is a
new and sensitive marker of kidney function in chronic kidney disease
patients and renal allograft recipients. Transplant Proc 2009, 41(1):158-161.
38. Dewitte K, Fierens C, Stockl D, Thienpont LM: Application of the Bland-
Altman Plot for Interpretation of Method-Comparison Studies: A Critical
Investigation of Its Practice. Clin Chem 2002, 48(5):799-801.
39. [http://www.ncbi.nlm.nih.gov/pubmed?
term=smertaUsingngalasanearlydiagnostictestofacutekidney2011].
40. de Vinuesa SG, Ortega M, Martinez P, Goicoechea M, Campdera FG, Luno J:
Subclinical peripheral arterial disease in patients with chronic kidney
disease: prevalence and related risk factors. Kidney Int Suppl 2005, 93(93):
S44-7.
41. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS: Chronic kidney disease as
a predictor of cardiovascular disease (from the Framingham Heart
Study). Am J Cardiol 2008, 102(1):47-53.
42. Giaginis C, Zira A, Katsargyris A, Klonaris C, Theocharis S: Clinical
implication of plasma neutrophil gelatinase-associated lipocalin (NGAL)
concentrations in patients with advanced carotid atherosclerosis. Clin
Chem Lab Med 2010, 48(7):1035-1041.
43. Falke P, Elneihoum AM, Ohlsson K: Leukocyte activation: relation to
cardiovascular mortality after cerebrovascular ischemia. Cerebrovasc Dis
2000, 10(2):97-101.
44. Forsblad J, Gottsater A, Persson K, Jacobsson L, Lindgarde F: Clinical
manifestations of atherosclerosis in an elderly population are related to
plasma neopterin, NGAL and endothelin-1, but not to Chlamydia
pneumoniae serology. Int Angiol 2002, 21(2):173-179.
45. Castro R, Rivera I, Blom HJ, Jakobs C, Tavares de Almeida I: Homocysteine
metabolism, hyperhomocysteinaemia and vascular disease: an overview.
J Inherit Metab Dis 2006, 29(1):3-20.
46. Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Pawlak K, Dobrzycki S:
Serum neutrophil gelatinase-associated lipocalin as a marker of renal
function in hypertensive and normotensive patients with coronary
artery disease. Nephrology (Carlton) 2008, 13(2):153-156.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2369/13/8/prepub
doi:10.1186/1471-2369-13-8
Cite this article as: Magnusson et al.: Plasma neutrophil gelatinase
associated lipocalin (NGAL) is associated with kidney function in
uraemic patients before and after kidney transplantation. BMC
Nephrology 2012 13:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Magnusson et al. BMC Nephrology 2012, 13:8
http://www.biomedcentral.com/1471-2369/13/8
Page 8 of 8
